Risk Adjusted Returns of Healthcare Venture Studios

There are now several venture studios that operate outside of traditional software - Redesign Health, Juxtapose, etc. The businesses these venture studios incubate and launch will likely exit for an EBITDA multiple one day (given the lower margin / growth profile vs. traditional software). I'm struggling to understand how these firm's generate returns that are sufficient to compensate for the risk of their model. It seems like they are taking on significant risk, comparable to seed stage investors, investing material sweat equity into building the platform, and have more highly concentrated portfolios but lack the large "unicorn" exit potential that traditionally allows the math of VC returns to pencil out (ie: one deal can return the entire fund). 

Does anyone have any insights into the returns of these types of firms and how to think about their investment strategy?

2 Comments
 

Based on the most helpful WSO content, here are some insights into the risk-adjusted returns and investment strategies of healthcare venture studios like Redesign Health and Juxtapose:

  1. Risk Profile:

    • These venture studios take on significant risk, similar to seed-stage investors.
    • They invest substantial sweat equity into building the platform.
    • They have more highly concentrated portfolios compared to traditional VCs.
  2. Return Potential:

    • Unlike traditional software ventures, the businesses incubated by healthcare venture studios are likely to exit for an EBITDA multiple due to their lower margin and growth profile.
    • This means they may lack the large "unicorn" exit potential that can return the entire fund in one deal.
  3. Investment Strategy:

    • The strategy involves incubating and launching businesses with a focus on healthcare, which inherently has different growth and margin characteristics compared to software.
    • The returns are driven by the ability to achieve exits at reasonable EBITDA multiples rather than relying on outlier "home run" exits.
  4. Challenges:

    • The main challenge is generating sufficient returns to compensate for the high risk of their model.
    • The lack of large exit potential makes it harder to achieve the high returns typically seen in traditional VC models.
  5. Market Dynamics:

    • The healthcare sector has unique dynamics, including regulatory challenges and longer development cycles, which can impact the return profile.
    • The focus on healthcare may provide some stability and predictability in returns, albeit at potentially lower multiples.

In summary, healthcare venture studios face significant risks and challenges in generating high returns due to the nature of their investments and the lack of large exit potential. Their investment strategy focuses on achieving reasonable EBITDA multiples, which may offer more stable but lower returns compared to traditional VC models.

Sources: Venture Capital Salary versus BB and Private Equity, What the f**k is VC even???, https://www.wallstreetoasis.com/forum/venture-capital/corporate-venture-capital-vs-independent-venture-capital-firms?customgpt=1, Q&A: Private Equity Investor at a Large Buyout Firm Focused on Growth and LBO Strategies, Q&A: Principal at Early-Stage VC Fund

I'm an AI bot trained on the most helpful WSO content across 17+ years.
 

Quia animi eaque aut praesentium illum. Magnam accusantium sint mollitia quia repellat ipsum sit. Eum eum qui et rem consequatur eaque. Ad aut quos magnam ut. Quod consequatur eveniet quos pariatur. Ut ipsa eos quos dignissimos sunt qui.

Eum a non dolorem adipisci ea omnis. Sequi voluptatem dicta doloremque in a. Dolores est autem non in eos ipsa modi.

Voluptatum et ipsam distinctio voluptas commodi ullam sunt. Molestias accusantium temporibus qui quaerat voluptatem dolores delectus voluptatem. Nesciunt et molestiae vero ullam nostrum. Accusamus dolorem deserunt voluptas minima rerum. Ratione fugit minus qui voluptatem et ut. Natus ipsa impedit quo in.

Career Advancement Opportunities

June 2026 Investment Banking

  • Evercore 01 99.4%
  • Moelis & Company 01 98.8%
  • JPMorgan 01 98.2%
  • Guggenheim Partners 01 97.7%
  • Morgan Stanley 07 97.1%

Overall Employee Satisfaction

June 2026 Investment Banking

  • Moelis & Company No 99.4%
  • Morgan Stanley 01 98.8%
  • Evercore 01 98.2%
  • BMO Capital Markets 12 97.6%
  • Banco Santander 01 97.1%

Professional Growth Opportunities

June 2026 Investment Banking

  • Moelis & Company No 99.4%
  • Evercore No 98.8%
  • Morgan Stanley 05 98.2%
  • JPMorgan No 97.7%
  • BMO Capital Markets 12 97.1%

Total Avg Compensation

June 2026 Investment Banking

  • Vice President (14) $434
  • Associates (43) $259
  • 3rd+ Year Analyst (8) $210
  • 2nd Year Analyst (22) $179
  • Intern/Summer Associate (13) $156
  • 1st Year Analyst (75) $151
  • Intern/Summer Analyst (67) $101
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

1
redever's picture
redever
99.2
2
BankonBanking's picture
BankonBanking
99.0
3
kanon's picture
kanon
99.0
4
Secyh62's picture
Secyh62
99.0
5
CompBanker's picture
CompBanker
98.9
6
DrApeman's picture
DrApeman
98.9
7
dosk17's picture
dosk17
98.9
8
Betsy Massar's picture
Betsy Massar
98.9
9
GameTheory's picture
GameTheory
98.9
10
bolo up's picture
bolo up
98.8
success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”